Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD
COPD (Chronic Obstructive Pulmonary Disease)The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to:
* Perform lung function and exercise tests
* Have ultrasound of their heart
* Have CT images of their lungs
* Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic)
The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
50 to 85
Participation Criteria
Inclusion Criteria:
* Patients with mild COPD (defined as having a postbronchodilator FEV1/FVC ratio \<0.70 and FEV1 ≥ 80% predicted
Exclusion Criteria:
* Pre-existing heart failure and pulmonary artery hypertension.
* Known thrombocytopenia.
* Resting blood pressure of \<90mmHg systolic and \<50 mmHg diastolic.
* Known sensitivity to prostanoids
* Severe hepatic insufficiency
Study Location
Clinical Physiology Laboratory
Clinical Physiology LaboratoryEdmonton, Alberta
Canada
Contact Study Team
- Study Sponsored By
- University of Alberta
- Participants Required
- More Information
- Study ID:
NCT06969573